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Multicomponent Reactions in Drug Discovery and Medicinal
Eelco Ruijter (1977) carried out his graduate
studies with Prof. Ludger Wessjohann at the
Vrije Universiteit (VU) Amsterdam and the
Leibniz Institute of Plant Biochemistry (Halle/
Saale, Germany) and was awarded his PhD in
2005. By then, he had joined Prof. Rob Liskamp’s
group at Utrecht University as a postdoctoral
fellow working on chemistry-based proteomics.
In December 2006, he returned to the VU
Amsterdam as a tenure track assistant
professor at the Department of Chemistry & Pharmaceutical
Sciences. He received tenure in 2012 and was promoted to
associate professor in 2018. His research interests include the
development of new synthetic strategies towards complex
molecules of high biological relevance making use of cascade
processes and asymmetric catalysis. He is author of 88 publications
in international, peer-reviewed scientific journals (h-index: 32) and
five book chapters, editor of two volumes in a book series, and co-
inventor of three patents.
Romano V.A. Orru obtained his PhD in 1994
with prof Ae. De Groot at the Agricultural
University in Wageningen, The Netherlands, on
synthetic methodology towards sesquiterpene
total syntheses. From 1996 to 2000 he worked
on synthetic applications of biotransformations
in the group of prof. K. Faber at the Technical
and Karl-Franszens Universities in Graz,
Austria. In 2000 he was appointed assistant
professor and later associate professor at the
VU Amsterdam. Since 2007, he holds the chair of Synthetic & Bio-
organic Chemistry in Amsterdam running a group of 15–20
researchers.Qualityof life hasincreasedtremendouslyoverthe pastcentury
and unquestionably one of the main drivers for that are the
amazing developments in medicine. Nowadays, people can
enjoy longer and healthier lives as effective treatment is avail-
able for many previously incurable diseases. Indeed, pharma-
ceuticals have come a long way from simple compounds like
paracetamol and aspirin to today’s modern drugs, with their*Corresponding author.
1 See Appendix A.
1740-6749/$ © 2018 Published by Elsevier Ltd. https://doi.org/10.1016/j.ddtec.2018.11.002 potency and selectivity molecules reflected in increasingly
complex molecular structures. However, as valuable as drugs
may be, they currently lack an important feature: the ability to
be produced in a sustainable and affordable way. Synthetic
chemistry, despite also having seen outstanding progress in the
last century, has not quite been able to keep up the pace with
the discoveries in medicine: in general, drugs are produced via
tedious, multistage, highly wasteful processes, often using
toxic materials. Thus, the manufacturing side of the pharma-
ceutical industry is cost- and resource-inefficient and environ-1
Drug Discovery Today: Technologies | Multicomponent Reactions in Drug Discovery and Medicinal Chemistry Vol. 29, 2018mentally unfriendly. Surely, the high value of the products –
the medicines – justifies the means, but improvements are
dearly needed in this area as well.
Developing more efficient techniques for synthesising
complex drug molecules is a painstaking process. Multicom-
ponent and other cascade reactions (processes comprising
several consecutive reactions in one pot) allow scientists to
carry out chemical syntheses in fewer steps than convention-
al approaches. Generally, they improve the eco-friendliness
and time/cost efficiency associated with the synthesis of
drugs and other high-value organic molecules. Therefore,
these one-pot processes have the potential to reduce our
environmental impact, as well as the overall costs associated
with producing life-saving medicines. A multicomponent
reaction, or MCR, is a specific type of cascade reaction that
combines three or more reactants in one reaction vessel to
form a new product. This product often contains all the
atoms that were present in the reactants. As a result, there
is very little waste or unwanted by-product formation com-
pared to more traditional syntheses. Therefore, MCRs are
powerful tools for the synthesis of complex, biologically
relevant molecules. The atom economy of MCRs, their con-
vergent character, operational simplicity, and the structural
diversity and complexity of the resulting products make this
chemistry exceptionally useful for discovery and optimisa-
tion processes in the pharmaceutical industry.
In this special issue, contributions from renowned (syn-
thetic) chemists highlight several aspects of MCRs in drug
discovery and medicinal chemistry. From the laboratory in
Genova a contribution of Luca Banfi & Renata Riva discusses
the application of biocatalysis to MCR processes in order to
address stereochemistry issues connected to many of these
cascade reactions. Another aspect is highlighted by Alex
Dömling and coworkers from the University of Groningen.
In their contribution efficient access to highly potent macro-
cyclic (semi)peptides is described. The MCR approach allows
quick synthesis of analogs facilitating SAR. A completely
different type of application is described by Thomas Müller
from University of Düsseldorf. His lab is known for the use of
MCR cascade sequences to produce luminescent materials,
which can be used to visualize pharmacologically important
processes in e.g. cells. Thomas Nielsen from the University of
Copenhagen in turn disclosed a very nice and to the point
entry to the use of the Petasis three-component reactions in
medicinal chemistry. Benzynes become more and more im-
portant as building blocks in MCR chemistry and the contri-
bution of Tracey Pirali and Marta Serafini from the Università2 www.drugdiscoverytoday.comdel Piemonte Orientale provides a brief introduction into that
emerging area.
The discovery of new variations of classical MCRs remains a
fruitful strategy for the development of new flexible multi-
component processes. Sunliang Cui and Bo Huang of Zhe-
jiang University discuss their use of ynamide as isocyanide
homologs in new MCRs based on the Ugi and Passerini
reactions. Andrei Yudin and Joanne Tan of the University
of Toronto highlight the use of borylated reagents in multi-
component chemistry and application of the resulting pro-
ducts in synthetic and medicinal chemistry. Erik Van der
Eycken and co-workers present an overview of gold-catalysed
cyclisation reactions of MCR products accessing complex
polycyclic scaffold structures. Finally, Rodolfo Lavilla and
Ouldouz Ghashghaei of the University of Barcelona together
with colleagues of the University of the Basque Country
review recent applications of the Povarov reaction in medici-
nal chemistry.
In summary, this special issue of Drug Discovery Today:
Technologies may serve as an excellent starting point for the
non-specialized medicinal chemist as an entry to MCRs in
drug discovery and medicinal chemistry. We hope you all
enjoy reading it and may try some of the chemistry yourself in
the lab!
Appendix A
Profile of the Synthetic & BioOrganic Chemistry Group
The research of the SyBOrCh group (http://syborch.com/)
focuses on sustainable synthetic method development employ-
ing cascade (or domino, tandem) processes. These are applied to
the diversity-oriented synthesis of small focused libraries of
high added value small molecules, including building blocks for
pharmaceuticals or ligands for catalysis. Since entering the field
the group has developed important novel entries in the highly
competitive area of multicomponent reactions (MCRs) and
strategies for diversity-oriented synthesis, often involving
bio- and transition metal catalysis. We especially focus on
mechanistic and stereochemical aspects, as well as on optimi-
zation toward robust procedures of high synthetic utility. The
group’s chemistry has proven successful in the synthesis of
potentially biologically active molecules (antitumor, antibio-
tics, hepatitis C) as well as ligands relevant to catalysis. Eelco
Ruijter and Romano Orru are leading players in the field of
multicomponent and cascade reactions for diversity-oriented
synthesis.
